about
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsService utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.Importance of the herpes simplex virus UL24 gene for productive ganglionic infection in mice.Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, coNumber needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder.Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: data from a clinical study that was terminated early.Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase.A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model.Effect of an amber mutation in the herpes simplex virus thymidine kinase gene on polypeptide synthesis and stability.Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation.Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugsConcomitant Oral Antihyperglycemic Agent Use and Associated Treatment Outcomes After Initiation of Insulin TherapyFluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot StudyConcentrated insulins: History and critical reappraisal
P50
Q33864322-8295B536-584F-4F56-9240-6A4256D32F98Q34543057-648A2E36-DED1-460A-878C-9124D393DA37Q35563634-11E36289-32C7-4246-8B65-48D20A128BCFQ36718685-380925CB-54F6-4439-ACBE-B5F260DC4EBDQ42673922-99D6C9B8-9B4D-425F-A2B8-22F32D5286F6Q42793334-D9C50111-A622-443F-9FEB-D1F5D5B6F5B1Q43243101-E0661F6A-008C-4D71-84AA-064C758AC725Q43280307-32CF5E4A-ACD8-4B93-913B-EA8CF6379331Q43661536-3C354855-9CC9-419E-8CEB-8FB223455C91Q44168453-51F617B6-DB92-4AB1-8DDF-A7B80619706AQ45122504-F63C975E-E773-466E-80AB-8A93230B8C09Q45784444-C05FBDD5-56F3-4500-BD00-ED4A7EDC6CC7Q45845070-0AF09FCE-4540-4287-BD48-BBF979377E62Q45846379-38825FE8-8DCB-4A7A-9B96-984447498938Q45846382-DA957A82-0878-44E8-91DE-E5368D7ED27CQ45889646-0D63E4D9-0900-4FE9-A055-63AF0CEE39BAQ46013607-19817FCA-B002-4A90-85E9-EEBC5A31AB4BQ46150815-03C7A27F-1C47-483A-80A3-D015C39EEC88Q55245090-BDCC74F6-575C-419E-9307-72C1D8CFE1D1Q58457876-A11BCDAD-D830-4A75-AAE5-7C9243FE8485Q58457892-720712E8-E51A-495C-B92E-83455E9D840FQ58457970-C5DE116A-AE8B-4D0C-8CA2-8769C5DA0798Q91839922-BA511C36-ED9D-4CCA-906A-C030B2E57DF4
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jennie G. Jacobson
@ast
Jennie G. Jacobson
@en
Jennie G. Jacobson
@es
Jennie G. Jacobson
@nl
Jennie G. Jacobson
@sl
type
label
Jennie G. Jacobson
@ast
Jennie G. Jacobson
@en
Jennie G. Jacobson
@es
Jennie G. Jacobson
@nl
Jennie G. Jacobson
@sl
altLabel
Jennie G Jacobson
@en
Jennie Grace Jacobson
@en
prefLabel
Jennie G. Jacobson
@ast
Jennie G. Jacobson
@en
Jennie G. Jacobson
@es
Jennie G. Jacobson
@nl
Jennie G. Jacobson
@sl
P106
P1153
35344742000
7402825862
P21
P31
P496
0000-0002-7489-7784